Detalhe da pesquisa
1.
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Br J Haematol
; 200(4): 451-461, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335984
2.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Br J Haematol
; 200(2): 175-186, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214090
3.
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Br J Haematol
; 198(3): 535-544, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35438802
4.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica
; 107(12): 2859-2869, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35615931
5.
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
Transfusion
; 62(5): 961-973, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35452143
6.
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Ann Hematol
; 101(10): 2241-2255, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36040480
7.
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Haematologica
; 105(3): 640-651, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31278207
8.
Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes.
Haematologica
; 105(3): 632-639, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171638
9.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol
; 187(3): 337-346, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271217
10.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood
; 129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
11.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer
; 124(14): 2956-2963, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
12.
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Cancer
; 123(22): 4403-4410, 2017 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28743166
13.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica
; 102(8): 1368-1377, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522576
14.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(5): 612-21, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083332
15.
Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.
Br J Haematol
; 174(1): 71-80, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27060881
16.
A randomized phase II trial of azacitidine +/- epoetin-ß in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Haematologica
; 101(8): 918-25, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27229713
17.
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cancer
; 121(10): 1637-44, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25586015
18.
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
Br J Haematol
; 170(3): 372-83, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25907546
19.
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
Blood
; 122(18): 3169-77, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24047651
20.
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Blood
; 119(14): 3211-8, 2012 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22343920